Clinical trial
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally…
NCT00217581 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00217581 |
|---|---|
| Title | Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer |
| Official title | Phase II Trial of Bevacizumab, Docetaxel, and Oxaliplatin in Gastric and Gastroesophageal Junction Cancer |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer |
| Intervention type | Biological, Drug |
| Interventions | Bevacizumab, Docetaxel, Oxaliplatin |
| Enrollment | 39 |
| Start date | Oct 1, 2004 |
| Primary completion | Nov 1, 2012 |
| Completion | Jan 1, 2013 |
| First posted | Sep 22, 2005 |
| Last update posted | Mar 26, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: